Solara clinical trial strategy platform recognized for transformative innovation
WALTHAM, MASS - Cytel Inc., a statistical software and advanced analytics provider in life sciences announces that Solara®, its clinical trial strategy platform, is the recipient of the 2022 Fierce Life Sciences Innovation Award for Technology Innovation. The prize, produced by Fierce Biotech and Fierce Pharma, showcases outstanding innovation driving industry transformation. Solara, the first-to-market platform for simulation-guided design, enables pharmaceutical sponsors to efficiently align on trial goals, navigate trial uncertainties and produce pressure-tested clinical trial designs that minimize costs and accelerate speed to market.
"Cytel's leadership position in statistical design gave us unique insight into unmet needs upstream during the planning and design stage of clinical trials,” said Josh Schultz, CEO of Cytel. "We integrated innovations in Solara that optimize trial designs while enhancing quantitative decision-making. This recognition by Fierce, a trusted leader in biopharma news, further validates Solara's ability to change how clinical trials are conceived and executed, ultimately accelerating patient access to new medicines.”
Solara combines Cytel’s proprietary algorithms developed over three decades with massive cloud compute power to overcome constraints in clinical trial planning and design. Using Solara, product development teams rapidly generate tens of thousands of trial models, representing thousands of design permutations. These are used to pressure-test against dozens of trial uncertainties, such as treatment effect and enrollment rate. In minutes, the platform’s high-speed processing capability simulates tens of millions of modeled events that might be observed during trial execution. Solara’s visualizations allow for easy review of the results and the ability to quantify tradeoffs.
Since its initial launch in 2021, Solara has been adopted by over 300 users at top 20 biopharma companies across the globe. Users reported saving 20x more time, while generating and reviewing 100x more models when compared with legacy tools and processes. The boost to productivity offers time and opportunity to further optimize designs. Meanwhile the expanded design space under consideration has consistently revealed highly-suitable design options left unexamined in the conventional approach. With Solara, users routinely reduce trial cost and/or duration by 10 to 20%, with estimated savings of more than $10 million for a single trial.
“High-speed cloud computing has allowed us to deliver simulation capabilities at a scale that previously hasn’t been available to product development teams,” said Scott Gaines, Cytel’s chief product officer and general manager of software. “Solara’s user-friendly interface and dynamic visualization offer a common language and workspace that enable more data-driven and collaborative discussions across product development functions and processes, which has proven to be an equally powerful innovation.”
Solara was chosen as the winner for the Technology category in the Fierce Life Sciences Innovation program based on its demonstrated effectiveness, technical innovation, competitive advantage, financial impact and true innovation.
To read the Innovation Report for the 2022 Fierce Innovation Awards: Life Sciences, click here.
Cytel is the largest provider of statistical software and advanced analytics for clinical trial design and execution. For over thirty-five years, Cytel’s scientific rigor and operational excellence have enabled biotech and pharmaceutical companies to navigate uncertainty, prove value and make confident, evidence-based decisions. Its experts deliver industry-leading software, data-driven analytics, real-world evidence and strategic consulting. Headquartered in Waltham, Massachusetts, Cytel has more than 2,000 employees across North America, Europe and Asia. For more information about Cytel, please visit us at www.cytel.com
About Fierce Life Sciences Innovation Awards
The Fierce Life Sciences Innovation Awards are offered for products that reflect effectiveness, innovation, competitive advantage and financial impact. As a part of its candidacy, Solara revealed the potential to maintain high standards of statistical rigor while saving sponsors many months and many millions of dollars of investment, across therapeutic areas.